In multiple sclerosis (MS), the body’s immune system attacks the myelin sheath, the protective layer surrounding nerve axons. Current MS therapies act by suppressing the immune system broadly—with sometimes serious side effects, including infection and cancer. However, a team of researchers led by Abdolmohamad Rostami, MD, PhD, professor and chair of neurology, has found a way to prevent immune cells from attacking myelin—while leaving the rest of the immune system intact. In mouse models of MS, their approach has halted disease progression.
"Paradigm-Changing Immunotherapy for Multiple Sclerosis,"
Thomas Jefferson University Research Magazine: Vol. 2:
1, Article 24.
Available at: https://jdc.jefferson.edu/researchmagazine/vol2/iss1/24